A Phase 3 interventional study of Dexamethasone, 0.4mg and Placebo plug with no drug in Allergic Conjunctivitis, sponsored by Ocular Therapeutix, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-07.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 44th largest by enrollment of the 90 interventional ones that give a count, is the only one that started in 2019, is one of 34 in phase 3, and was the 77th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dexamethasone, 0.4mg
Device: Placebo plug with no drug
Ophthalmic Insert
Also known as: OTX-DP
Ophthalmic Insert
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion)
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit Increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
Time frame: 3 minutes
Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6 (7 Days Post-insertion)
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
Time frame: 5 minutes
Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6 (7 Days Post-insertion)
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
Time frame: 7 minutes
| Milestone | OTX-DP, 0.4 mg | Placebo |
|---|---|---|
| Started | 48 | 48 |
| Completed | 44 | 43 |
| Not completed | 4 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: No insert | 1 | 0 |
| Withdrew: Only 1 insert | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit Increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
| units on a scale | OTX-DP | Placebo |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion) | 1.80 (1.51 to 2.08) | 2.69 (2.40 to 2.98) |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
| units on a scale | OTX-DP | Placebo |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6 (7 Days Post-insertion) | 1.73 (1.45 to 2.00) | 2.72 (2.44 to 3.01) |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0 = None 0.5 = An intermittent tickle sensation possibly localized in the corner of the eye 1.0 = An intermittent tickle sensation involving more than just the corner of the eye 1.5 = An intermittent all-over tickling sensation 2.0 = A mild continuous itch (can be localized) without desire to rub 2.5 = A moderate, diffuse continuous itch with desire to rub 3.0 = A severe itch with desire to rub 3.5 = A severe itch improved with minimal rubbing 4.0 = An incapacitating itch with an irresistible urge to rub 0.5 unit increments ARE allowed
| units on a scale | OTX-DP | Placebo |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6 (7 Days Post-insertion) | 1.72 (1.43 to 2.00) | 2.71 (2.43 to 2.99) |
Collected over 30 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-DP | 0/48 (0%) | 0/48 (0%) | 16/48 (33.3%) |
| Placebo | 0/48 (0%) | 0/48 (0%) | 14/48 (29.2%) |
| Event | OTX-DP | Placebo |
|---|---|---|
| Treatment Emergent Adverse EventsEye disorders | 16/48 | 14/48 |
| Age, Categorical(Participants) | OTX-DP | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 47 | 45 | 92 |
| >=65 years | 1 | 3 | 4 |
| Age, Continuous(years) | OTX-DP | Placebo | Total |
|---|---|---|---|
| Mean | 43.8 ± 12.45 | 46.0 ± 12.92 | 44.9 ± 12.67 |
| Sex: Female, Male(Participants) | OTX-DP | Placebo | Total |
|---|---|---|---|
| Female | 27 | 24 | 51 |
| Male | 21 | 24 | 45 |
| Race (NIH/OMB)(Participants) | OTX-DP | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 17 | 31 |
| White | 32 | 29 | 61 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | OTX-DP | Placebo | Total |
|---|---|---|---|
| United States | 48 | 48 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2019 to primary completion in Feb 2020, 6 months.
Results were first posted in Oct 2021, 1 year 7 months after primary completion.
Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 6 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone